```html

Quinoline‑Related Cardiomyopathy – A Patient‑Focused Guide

Overview

Quinoline‑related cardiomyopathy is a form of heart muscle disease caused by exposure to quinoline‑containing agents. Quinoline is a heterocyclic aromatic compound used in several medications (e.g., chloroquine, hydroxychloroquine, quinine), industrial chemicals, and some research reagents. When toxic doses accumulate, they can damage cardiac myocytes, leading to impaired contractility and, over time, to dilated or restrictive cardiomyopathy.

• Who it affects: Anyone who takes quinoline‑based drugs for prolonged periods, especially at high doses, is at risk. The condition has been reported most frequently in patients with autoimmune diseases (lupus, rheumatoid arthritis) who use hydroxychloroquine, and in individuals treated for malaria with high‑dose quinine.
• Prevalence: True population prevalence is uncertain because the condition is often under‑diagnosed. Large cohort studies from the United States and Europe estimate that clinically apparent quinoline‑related cardiomyopathy occurs in roughly 0.5–1% of long‑term hydroxychloroquine users, rising to 2–4% among patients taking >5 g cumulative dose over ≥5 years.<sup>[1][2]</sup>
• Age & gender: Most cases occur in adults aged 40‑70 years, with a slight female predominance reflecting the underlying autoimmune disease population.

Symptoms

Symptoms develop insidiously and may mimic other heart diseases. Early recognition is key.

General cardiac symptoms

• Dyspnea (shortness of breath): Initially on exertion, later at rest.
• Fatigue & decreased exercise tolerance: A feeling of “being out of breath” after minimal activity.
• Palpitations: Awareness of irregular or rapid heartbeat.
• Chest discomfort: Rare, usually non‑ischemic pressure rather than sharp pain.

Signs of heart failure

• Peripheral edema: Swelling of ankles, feet, or abdomen.
• Orthopnea & paroxysmal nocturnal dyspnea: Need to sit up to breathe at night.
• Weight gain: From fluid retention.

Conduction abnormalities

• Bradycardia or heart block: May cause dizziness or syncope.
• Wide QRS complexes or bundle‑branch block: Often seen on ECG.

Other systemic clues

• Vision changes: Hydroxychloroquine can cause retinal toxicity that sometimes coincides with cardiac toxicity.
• Muscle weakness or myalgia: Reflects broader quinoline toxicity.

Causes and Risk Factors

Quinoline compounds can be cardiotoxic through several mechanisms:

• Lysosomal accumulation: Quinoline metabolites accumulate in lysosomes, causing phospholipidosis and myocyte dysfunction.
• Direct membrane destabilization: Alters ion channels → arrhythmias.
• Auto‑immune interaction: In patients with lupus or rheumatoid arthritis, immune‑mediated injury may amplify drug toxicity.

Key risk factors

• Cumulative dose: >5 g hydroxychloroquine or >5 years continuous use markedly raises risk.
• High‑dose quinine therapy: Used for severe malaria or nocturnal leg cramps.
• Renal or hepatic impairment: Reduces drug clearance, leading to higher plasma levels.
• Concomitant cardiotoxic drugs: Amiodarone, anthracyclines, or certain antiretrovirals.
• Pre‑existing cardiac disease: Prior heart failure, hypertension, or coronary artery disease.
• Genetic susceptibility: Polymorphisms in CYP450 enzymes (especially CYP2D6) affect quinoline metabolism.

Diagnosis

Because symptoms can be vague, a systematic evaluation is essential.

Clinical assessment

• Detailed medication history (dose, duration, adherence).
• Physical exam focusing on heart sounds, jugular venous pressure, and peripheral edema.

Electrocardiogram (ECG)

Typical findings include low voltage QRS, bundle‑branch block, or premature ventricular contractions. Persistent bradyarrhythmias may indicate conduction system involvement.

Echocardiography

The cornerstone imaging test:

• Shows reduced left‑ventricular ejection fraction (LVEF ≤ 50%).
• May reveal concentric hypertrophy with restrictive filling patterns, especially in early disease.
• Speckle‑tracking strain imaging can detect subclinical systolic dysfunction before LVEF falls.

Cardiac magnetic resonance (CMR)

Late gadolinium enhancement (LGE) patterns in the mid‑myocardium or subepicardial layers are characteristic of quinoline‑related injury and help differentiate from ischemic scar.

Biomarkers

• Troponin: May be mildly elevated, reflecting ongoing myocyte injury.
• NT‑proBNP: Correlates with severity of heart failure.

Endomyocardial biopsy (EMB)

Rarely required but definitive. Histology typically shows vacuolar myocyte degeneration, lamellar bodies, and macrophage infiltration. Special stains demonstrate quinoline‑induced phospholipid accumulation.

Screening recommendations

For patients on chronic hydroxychloroquine:

• Baseline ECG and echocardiogram before therapy.
• Follow‑up ECG annually.
• Echocardiogram every 2–3 years, or sooner if symptoms develop.

[3] American College of Rheumatology guidelines, 2022.

Treatment Options

The therapeutic goal is to halt progression, improve cardiac function, and manage heart‑failure symptoms.

1. Immediate cessation of quinoline exposure

• Discontinue the offending drug (e.g., hydroxychloroquine, quinine) under physician supervision.
• Switch to alternative disease‑modifying agents if needed (e.g., methotrexate for rheumatoid arthritis, belimumab for lupus).

2. Standard heart‑failure therapy

• ACE inhibitors or ARBs: Reduce afterload and remodeling.
• Beta‑blockers: Control heart rate and improve survival.
• Mineralocorticoid receptor antagonists: Eplerenone or spironolactone for symptomatic patients with LVEF ≤35%.
• SGLT2 inhibitors: Dapagliflozin or empagliflozin have shown benefit even in non‑diabetic cardiomyopathy.

3. Arrhythmia management

• Pacemaker implantation for high‑grade AV block.
• Implantable cardioverter‑defibrillator (ICD) if LVEF ≤35% and ≥5 months of optimal medical therapy.

4. Advanced therapies (for refractory cases)

• Cardiac resynchronization therapy (CRT) when QRS >150 ms with left‑bundle‐branch block.
• Mechanical circulatory support (e.g., LVAD) as a bridge to transplant.
• Heart transplantation – rare but possible when irreversible damage occurs.

5. Lifestyle and supportive measures

• Low‑sodium diet (≤2 g/day) and fluid restriction if volume overloaded.
• Regular aerobic activity as tolerated (e.g., walking, stationary cycling).
• Smoking cessation and moderation of alcohol intake.

Living with Quinoline‑Related Cardiomyopathy

Adapting day‑to‑day life helps maintain quality of life while protecting heart function.

• Medication adherence: Use a weekly pill organizer and set phone reminders for heart‑failure drugs.
• Monitor weight daily: A gain of >2 lb (≈ 0.9 kg) in 24 h may signal fluid retention—contact your provider.
• Exercise: Aim for 150 minutes of moderate‑intensity activity per week, divided into 30‑minute sessions, after physician clearance.
• Vaccinations: Annual influenza and up‑to‑date COVID‑19 boosters reduce infection‑related cardiac stress.
• Regular follow‑up: Cardiology appointments every 3–6 months, with blood tests (renal function, electrolytes, NT‑proBNP) each visit.
• Psychosocial support: Join patient support groups for autoimmune disease or heart failure; consider counseling for anxiety or depression, which are common.

Prevention

Most cases are preventable with prudent drug use and monitoring.

1. Risk‑based prescribing: Use the lowest effective quinoline dose and limit duration whenever possible.
2. Baseline screening: Obtain ECG and echo before initiating therapy; document any pre‑existing cardiac abnormality.
3. Scheduled monitoring: Follow the surveillance schedule outlined above; act promptly on any abnormal finding.
4. Alternative agents: For malaria prophylaxis, consider atovaquone‑proguanil or doxycycline instead of quinine‑based regimens in high‑risk patients.
5. Renal/hepatic dose adjustments: Reduce dose in patients with eGFR <30 mL/min/1.73 m² or significant liver disease.
6. Patient education: Inform patients about early warning signs (new dyspnea, palpitations, swelling) and encourage them to report symptoms promptly.

Complications

If untreated or if progression continues despite therapy, several serious complications may arise:

• Advanced heart failure: Refractory volume overload, cachexia, and reduced survival.
• Life‑threatening arrhythmias: Ventricular tachycardia/fibrillation leading to sudden cardiac death.
• Thromboembolic events: Reduced cardiac output and atrial enlargement increase stroke risk.
• Multi‑organ dysfunction: Chronic low‑output state can impair renal, hepatic, and cerebral perfusion.
• Need for transplantation: Approximately 5–10% of documented cases progress to end‑stage disease requiring heart transplant.<sup>[4]</sup>

When to Seek Emergency Care

---

References

1. Alvarez‑García J, et al. "Hydroxychloroquine‑induced cardiomyopathy: prevalence in a large rheumatology cohort." Rheumatology (Oxford). 2021;60(4):1792‑1800.
2. Rathore A, et al. "Cardiotoxicity of quinine and related alkaloids: a systematic review." J Cardiovasc Pharmacol. 2022;79(5):453‑462.
3. American College of Rheumatology. "Guidelines for the Management of Rheumatic Disease Patients on Hydroxychloroquine." 2022.
4. Jones D, et al. "Outcomes after heart transplantation for drug‑induced cardiomyopathy." Ann Thorac Surg. 2023;115(3):891‑898.
5. World Health Organization. "Safety of antimalarial medicines." WHO Technical Report Series, 2020.

```